Clinical Trials
6 trialsNCT07585747 2026-05-14
CUREMZL002
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Not yet recruiting
NCT07554898 2026-05-11
Ultra-low-dose Radiation Therapy Followed by Orelabrutinib as First-line Treatment for Stage â… -â…¡ MALT Lymphoma
Zhejiang Cancer Hospital
Phase 2 Recruiting
NCT04989621 2026-04-23
Orelabrutinib Plus Rituximab Followed by Maintenance With Orelabrutinib for Relapsed and Refractory Follicular Lymphoma(RR FL)
Sun Yat-sen University
Phase 2 Recruiting
NCT07480863 2026-04-02
Treatment of Orelabrutinib+Hi-CVP Regimen for Previously Untreated MZL
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Active not recruiting
NCT07499271 2026-03-30
Genetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 Mutation
The First Affiliated Hospital of Soochow University
Phase 2 Recruiting
NCT06793189 2026-03-24
MZL-IPI Risk-adapted Targeted Therapy in Untreated MZL
Ruijin Hospital
Phase 2 Recruiting